8-K

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): November 30, 2009

ThermoGenesis Corp.
__________________________________________
(Exact name of registrant as specified in its charter)

Delaware	333-82900	94-3018487
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)
2711 Citrus Rd., Rancho Cordova, California		95742
_________________________________ (Address of principal executive offices)		___________ (Zip Code)

Registrant’s telephone number, including area code: 916-858-5100

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

On November 30, 2009 ThermoGenesis Corp. ("Thermo") entered into an Amendment to the Amended and Restated International Distribution Agreement Concerning the AXP Platform with GE Healthcare Bio-Sciences A.B., a GE Healthcare company ("GEHC"). Under the terms of the amendment, the parties agreed to extend the deadline for termination on renewal notification to eleven (11) months prior to the contract termination date of December 31, 2010, from the original deadline of twelve (12) months.

Item 9.01 Financial Statements and Exhibits.

10. Amendment to Amended and Restated International Distribution Agreement Concerning the AXP Platform dated November 17, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ThermoGenesis Corp.
December 3, 2009	By:	Matthew T. Plavan
		Name: Matthew T. Plavan
		Title: EVP, COO & CFO

Exhibit Index

Exhibit No.	Description
10	Amendment to Amended and Restated International Distribution Agreement Concerning the AXP Platform

EX-10

Amendment to Amended and Restate International Distribution
Agreement concerning the AXP Platform

This Amendment to the Agreement is made effective November 17, 2009 (“Effective Date”), by and between,

1. ThermoGenesis Corp., having its address at 2711 Citrus Road, Rancho Cordova, CA 95742, USA (“TGC”), and

2. GE Healthcare Bio-Sciences AB, a GE Healthcare company having its address at Björkgatan 30, SE-751 84 Uppsala, Sweden (“GEHC”).

Recitals

A. The Parties have entered into an Amended and Restated International Distribution Agreement, dated May 2, 2008 (the “Agreement”).

B. The Parties wish to have the Agreement amended in accordance with the provisions below.

Considering the above the Parties have entered into the following amendment to the Agreement (the “Amendment”).

Amendment

1. Terms not otherwise defined in this Amendment shall have the meanings defined in the Agreement.

2. Except as expressly amended herein, all terms and conditions of the Agreement shall remain in full force and effect.

3. The Amendment shall be effective as from the Effective Date.

4. Section 19.1 shall be deleted in its entirety and replaced by the following:

“This Agreement shall commence as the Effective Date and shall continue thereafter until December 31, 2010. Unless terminated in writing by either party no less than eleven (11) months before expiration of the then-current term, the term of this Agreement shall automatically be prolonged for two (2) year periods at a time.”

This Amendment has been executed in two originals whereof the Parties have taken one each.
THERMOGENESIS CORP.	GE HEALTHCARE BIO-SCIENCES AB

By:	/s/: J. Melville Engle	By:	/s/: Magnus Lundgren
Name:	JM Engle	Name:	Magnus Lundgren
Title:	CEO	Title:	Global Sourcing Executive
Date:	11/18/09	Date:	11/30/09